Norges Bank Purchases New Position in TransMedics Group, Inc. (NASDAQ:TMDX)

Norges Bank bought a new stake in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 366,661 shares of the company's stock, valued at approximately $22,861,000. Norges Bank owned 1.09% of TransMedics Group as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in the company. Quarry LP raised its holdings in shares of TransMedics Group by 557.1% in the 3rd quarter. Quarry LP now owns 368 shares of the company's stock valued at $58,000 after buying an additional 312 shares during the period. National Bank of Canada FI grew its position in TransMedics Group by 174.7% in the 3rd quarter. National Bank of Canada FI now owns 412 shares of the company's stock valued at $65,000 after acquiring an additional 262 shares in the last quarter. Hager Investment Management Services LLC purchased a new stake in TransMedics Group during the fourth quarter worth about $33,000. Sachetta LLC acquired a new stake in shares of TransMedics Group during the fourth quarter worth about $40,000. Finally, AlphaQuest LLC purchased a new position in shares of TransMedics Group in the fourth quarter valued at approximately $52,000. 99.67% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

TMDX has been the topic of a number of recent research reports. JPMorgan Chase & Co. reaffirmed a "neutral" rating and set a $75.00 price objective (down previously from $116.00) on shares of TransMedics Group in a research report on Tuesday, December 17th. Canaccord Genuity Group reissued a "buy" rating and set a $104.00 target price on shares of TransMedics Group in a research note on Tuesday, March 11th. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of TransMedics Group in a research report on Wednesday, March 26th. Three equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $122.70.

TransMedics Group Stock Up 5.5 %

Shares of TMDX traded up $4.21 during mid-day trading on Friday, reaching $80.58. The company's stock had a trading volume of 1,036,118 shares, compared to its average volume of 1,331,626. The company's 50 day moving average is $70.94 and its 200 day moving average is $81.62. The stock has a market cap of $2.71 billion, a PE ratio of 85.72 and a beta of 2.14. TransMedics Group, Inc. has a 12-month low of $55.00 and a 12-month high of $177.37. The company has a debt-to-equity ratio of 2.42, a current ratio of 8.20 and a quick ratio of 7.33.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.